Everything published about Cagrilintide: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 5 mg | from 2 200 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
Cagrilintide is a long-acting amylin analogue studied for appetite control and weight management. It works through satiety pathways that differ from GLP-1, making it an important subject in both single-agent and combination research.
An investigational peptide acting through amylin-related receptors. Its research programme focuses on reducing food intake and helping sustain weight reduction.
A distinct appetite-focused peptide with dose-dependent weight-loss results in clinical studies. Its main point of interest is amylin signalling, both alone and alongside GLP-1 therapy.
At 26 weeks, average weight reduction reached 10.8% in the 4.5 mg group, compared with 3.0% with placebo. The effect was dose-related. These results describe cagrilintide alone; combination results should be reported separately.
Once-weekly subcutaneous schedules: Weeks 1–4: 0.25 mg weekly Weeks 5–8: 0.5 mg weekly Weeks 9–12: 1 mg weekly Weeks 13–16: 1.7 mg weekly From week 17: 2.4 mg weekly This is a commonly discussed titration schedule. Phase 2 separately tested target doses of 0.3, 0.6, 1.2, 2.4 and 4.5 mg over 26 weeks; phase 3 studied 2.4 mg over 68 weeks, alone or with semaglutide.
Nausea, constipation, diarrhoea and injection-site reactions can occur. Tolerability varies with dose and escalation.
Cagrilintide works through amylin-related satiety signalling; semaglutide works through GLP-1. Combination trials explore the two together for complementary appetite control.
from 2 200 000 ₫ for 5 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.